VDCR as a treatment option for refractory or relapsed multiple myeloma in Bortezomib pretreated patients, a single center experience

被引：0
|
作者：
Dobrosch, L. [1 ]
Hahn-Ast, C. [1 ]
Mayer, K. [1 ]
von Lilienfeld-Toal, M. [1 ]
Brossart, P. [1 ]
Janzen, V [1 ]
机构：
[1] Univ Klinikum Bonn, Med Klin 3, Bonn, Germany
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2016年 / 39卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P543
引用
收藏
页码：162 / 162
页数：1
相关论文
共 50 条
  • [1] Bortezomib in relapsed and refractory multiple myeloma patients.: Experience of a single center
    Calabrese, E.
    Gallucci, C.
    Federico, V
    Mohamad, A.
    Foa, R.
    Petrucci, M. T.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 : 151 - 151
  • [2] Bortezomib and dexamethasone for Japanese patients with relapsed and refractory multiple myeloma: a single center experience
    Igarashi, Natsue
    Chou, Takaaki
    Hirose, Takayuki
    Imai, Yousuke
    Ishiguro, Takuro
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2010, 92 (03) : 518 - 523
  • [3] Bortezomib and dexamethasone for Japanese patients with relapsed and refractory multiple myeloma: a single center experience
    Natsue Igarashi
    Takaaki Chou
    Takayuki Hirose
    Yousuke Imai
    Takuro Ishiguro
    International Journal of Hematology, 2010, 92 : 518 - 523
  • [4] Bortezomib in relapsed/refractory myeloma patients: A single-center experience
    Grasso, M.
    Tavera, S.
    Bonferroni, M.
    Calvi, R.
    Rapezzi, D.
    Gallamini, A.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 : 149 - 150
  • [5] CARFILZOMIB TREATMENT IN RELAPSED/REFRACTORY MULTIPLE MYELOMA: SINGLE CENTER EXPERIENCE
    Uysal, A.
    Ozkan, M. Comert
    Soyer, N. Akad
    Sahin, F.
    Vural, F.
    Tobu, M.
    Tombuloglu, M.
    Saydam, G.
    LEUKEMIA RESEARCH, 2016, 49 : S29 - S30
  • [6] Daratumumab for the Treatment of Relapsed/Refractory Multiple Myeloma: A Single Center Experience
    Jimenez-Zepeda, Victor
    Duggan, Peter
    Neri, Paola
    Luider, Joanne
    Tay, Jason
    Bahlis, Nizar J.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2017, 17 (01): : E67 - E68
  • [7] Hemostatic effects of bortezomib treatment in patients with relapsed or refractory multiple myeloma
    Zangari, Maurizio
    Guerrero, Jose
    Cavallo, Federica
    Prasad, H. Keshava
    Esseltine, Dixie
    Fink, Louis
    HAEMATOLOGICA, 2008, 93 (06) : 953 - 954
  • [8] Treatment Options for Patients With Heavily Pretreated Relapsed and Refractory Multiple Myeloma
    Dimopoulos, Meletios-Athanasios
    Richardson, Paul
    Lonial, Sagar
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 (07): : 460 - 473
  • [9] BORTEZOMIB MAINTENANCE TREATMENT IN PATIENTS WITH MULTIPLE MYELOMA-A SINGLE CENTER EXPERIENCE
    Micheva, I.
    Dimitrova, S.
    Rachev, R.
    Varbanov, H.
    Mehmed, M.
    Gerov, V.
    Antonov, A.
    Gercheva, L.
    HAEMATOLOGICA, 2016, 101 : 796 - 796
  • [10] Carfilzomib experience in relapsed/refractory multiple myeloma: a single-center experience
    Uysal, Ayse
    Akad Soyer, Nur
    Ozkan, Melda
    Sahin, Fahri
    Vural, Filiz
    Tobu, Mahmut
    Tombuloglu, Murat
    Saydam, Guray
    TURKISH JOURNAL OF MEDICAL SCIENCES, 2018, 48 (01) : 80 - 83
12345